PolyPid (FRA:2PV) Moat Score: 3/10 (As of Jun. 26, 2026)


FRA:2PV PolyPid Ltd FRA:2PV
14 GF Score
Price €3.99
! 1 Warning Sign
View Full Analysis

What is PolyPid Moat Score?

PolyPid FRA:2PV -9.43% 14 Moat Score is 3 as of Jun. 26, 2026. GuruFocus rates FRA:2PV with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, PolyPid ranks better than 75.5% on this metric.

PolyPid has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

PolyPid has No Moat: PolyPid Ltd has some proprietary drug delivery technology, but faces significant competition and regulatory challenges. The company lacks strong market share, customer loyalty, and pricing power to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PolyPid might have No Moat - Very weak/transient advantages.

PolyPid  (FRA:2PV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PolyPid Moat Score Related Terms

FRA:2PV vs LONA, ANIX, SGMO: Moat Score Comparison

For the Biotechnology subindustry, PolyPid's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPid Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's Moat Score distribution charts can be found below:

* The bar in red indicates where PolyPid's Moat Score falls into.


FRA:2PV
14GF Score
PolyPid Ltd FRA:2PV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
PolyPid (FRA:2PV) has a Moat Score of 3 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PolyPid ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is PolyPid's Moat Score too high?
PolyPid's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. PolyPid's value of 3 is 50% above this industry median. Based on the distribution chart, PolyPid ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PolyPid has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does PolyPid's Moat Score compare to LONA and ANIX?
According to the Biotechnology industry distribution chart, PolyPid ranks #344 out of 1404 companies for Moat Score. This places PolyPid in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. PolyPid's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PolyPid's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PolyPid's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPid stock overvalued right now?
PolyPid (FRA:2PV) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. PolyPid's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PolyPid (FRA:2PV), the current Moat Score is 3 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PolyPid Business Description

Other Exchanges PYPD:USA
Address 18 Hasivim Street, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
14GF Score

Get the complete analysis for FRA:2PV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price